NCT04375124

Treatment of Angiotensin Peptide (1-7) for COVID-19

Evaluation of the Possible Role of Angiotensin Peptide (1-7) on Treatment of COVID-19

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 9 (actual)
• Sponsor: Kanuni Sultan Suleyman Training and Research Hospital · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Detailed description

Novel Coronavirus is reported to cause COVID-19, recently. It's known that this virus uses ACE (angiotensin converting enzyme) 2 receptors to enter human cells and also blocks the activity of ACE 2. Upon these data the investigators hypothesize that, mortal hyper-inflammation state which is shown in COVID-19 cases, can be a result of angiotensin peptide (1-7) deficiency. Therefore, the aim of this study is to evaluate the possible effect of plasma derived angiotensin peptide (1-7) supplementation on treatment of COVID-19 cases.

Conditions

• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	Biological/Vaccine: Angiotensin peptide (1-7) derived plasma	angiotensin peptide (1-7) derived plasma will be given to COVID-19 positive participants

Timeline

• Start date: 2020-04-25
• Primary completion: 2020-08-31
• Completion: 2020-09-30
• First posted: 2020-05-05
• Last updated: 2022-04-01

Locations

1 site across 1 country: Turkey (Türkiye)